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ABSTRACT 
 
On March 11, 2004, the Food and Drug Administration (FDA) pronounced that dietary supplement 
products containing androstenedione were adulterated new dietary ingredients under the Dietary 
Supplement Health and Education Act of 1994 (DSHEA).  The FDA issued a press release, held a 
news conference, and sent warning letters to 23 companies that had manufactured, marketed or 
distributed the products containing androstenedione.  In its warning letters, FDA threatened possible 
enforcement actions for noncompliance.  The authors have looked at the warning letters, statutes, 
regulations, and media reports to analyze the legal grounds and standards upon which FDA acted 
against androstenedione and question the appropriateness of the action taken.  They have also 
looked at the negative impact that FDA’s lack of communication and cooperation with Industry is 
having upon the fitness nutrition industry and the marketing of dietary supplements containing new 
dietary ingredients.  The authors also suggest what might be done to ameliorate this escalating 
problem including more cooperation between FDA and Industry and more research into the benefits 
and use of supplement products.  Sports Nutrition Review Journal. 1(1):52-60, 2004. 
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INTRODUCTION 
 
On March 11, 2004, the Food and Drug 
Administration (FDA) pronounced that 
dietary supplement products containing 
androstenedione were adulterated new dietary 
ingredients under the Dietary Supplement 
Health and Education Act of 1994 (DSHEA).  
Despite the lack of evidence of an imminent 
health hazard and instead of the formal 
administrative procedure of issuing a 
proposed rule and inviting public comment, 
FDA took unilateral action, issued a press 
release, held a news conference, and sent 
warning letters to 23 companies that had 
manufactured, marketed or distributed the 
products containing androstenedione.  In its 
warning letters, FDA threatened possible 
enforcement actions for noncompliance.  The 
effect was to cause retailers, manufacturers 
and distributors alike to cease selling products 
containing androstenedione without FDA 
having had meaningful dialogue with Industry 
before taking action.  This action, along with 
others of FDA in the past, is sadly illustrative 
of the lack of cooperation and communication 
that exists between FDA and Industry.  
FDA’s antagonistic attitude towards dietary 
supplements in general and the fitness 
nutrition industry in particular could result in 
an increasing encroachment upon DSHEA. 
 
This attitude, combined with sensationalized 
media reports, anti-supplement leanings by 
some members of Congress, and a general 
institutionalized bias against alternative health 
approaches, has created an environment in 
which the freedoms of Americans to make 
their own health choices under DSHEA are 
now in grave jeopardy.   Sports Nutrition Review Journal. 1 (1):52-60, 2004. (www.sportsnutritionsociety.org) 
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This article will analyze the legal grounds and 
standards upon which FDA acted against 
androstenedione.  It will look at the negative 
impact that FDA’s lack of communication 
and cooperation with Industry is having upon 
the fitness nutrition industry and the 
marketing of dietary supplements containing 
new dietary ingredients.  Finally, it will 
suggest what might be done to ameliorate 
these escalating problems.  
 
PUBLIC HEALTH PROTECTIONS ON 
DIETARY SUPPLEMENTS PROVIDED 
UNDER DSHEA     
 
In 1994, DSHEA
3 was passed with the 
unanimous consent of Congress.  As 
discussed in a recent law review article, 
FDA’s anti-supplement tactics provoked a 
groundswell of legislative criticism ultimately 
leading to DSHEA:
4  
 
DSHEA was enacted because FDA was 
viewed as distorting the law that existed 
before DSHEA to try improperly to deprive 
the public of safe and popular dietary 
supplement products. … In its official report 
about the need for DSHEA to curtail 
excessive regulation of dietary supplements 
by FDA, the Senate Committee on Labor and 
Human Resources … stated explicitly “in 
fact, FDA has been distorting the law in its 
actions to try to prevent the marketing of safe 
dietary supplement substances.” 
5  The Senate 
Committee also concluded, “FDA has 
attempted to twist the statute [i.e., the 
provisions of the FDCA, as it then existed] in 
what the Committee sees as a result-oriented 
effort to impede the manufacture and sale of 
dietary supplements.”
6       
 
DSHEA represented a sharp rebuke to FDA’s 
unreasonable regulatory tactics.  It was FDA’s 
own actions that brought about the need for 
DSHEA.  However, DSHEA did not leave 
FDA paralyzed.  Despite media statements to 
the contrary, the industry is not an 
unregulated industry.  In fact, DSHEA 
ensured FDA’s authority to provide legitimate 
protections for the public health.  The Food, 
Drug, and Cosmetic Act (FDCA)
7 prohibits 
introducing adulterated products into 
interstate commerce.
8  The penalties for a first 
conviction can include a fine of up to $1,000, 
imprisonment for up to one year, or both.
9  
Subsequent convictions, or convictions for 
offenses committed with the intent to defraud 
or mislead, can include fines of up to $10,000, 
imprisonment of up to three years, or both.
10   
 
Several grounds exist by which unsafe dietary 
supplements can be deemed “adulterated”.
11  
While the Secretary of Health and Human 
Services has the power to declare a dangerous 
supplement to be an “imminent hazard” to 
public health or safety and suspend sales of 
the product,
12 FDA also has the authority to 
protect consumers from dietary supplements 
that don’t present an imminent hazard to the 
public but do present certain risks of illness or 
injury to consumers.  Two provisions are 
relevant to our examination.    
 
The first provision, which applies to all 
dietary supplements, states that a supplement 
shall be deemed adulterated if it presents “a 
significant or unreasonable risk of illness or 
injury under … conditions of use 
recommended or suggested in labeling, or … 
if no conditions of use are suggested or 
recommended in the labeling, under ordinary 
conditions of use.”
13  The standard doesn’t 
require proof that consumers have actually 
been harmed, or even that a product will harm 
anyone.  It was under this provision that FDA, 
after seven years, numerous criticisms 
including a negative report from the General 
Accounting Office
14 and a storm of public 
debate, concluded that dietary supplements 
containing ephedra presented an unreasonable 
risk.  However, the conclusion FDA drew and 
its reasoning to declare products containing 
ephedra adulterated utilized a new and novel 
approach that distorts the definition of 
significant or unreasonable risk.  In the case 
of ephedra, FDA did an analysis of whether 
the product’s known or reasonably likely risks 
outweigh its known or reasonably likely 
benefits.  Thus, this is no longer a straight 
safety analysis, but is now a risk/benefit Sports Nutrition Review Journal. 1 (1):52-60, 2004. (www.sportsnutritionsociety.org) 
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analysis, which is not what is called for in the 
statute.  Even though ephedra had been shown 
beneficial for short-term weight loss, FDA 
used this standard to conclude that these 
benefits did not outweigh the risks that FDA 
felt ephedra products posed.
15   Pending 
litigation challenging FDA’s actions will 
determine whether or not FDA’s analysis is 
correct.
16  If this standard withstands legal 
challenge, then this definition will apply to all 
other supplements and many popular and less 
controversial supplements will also be at risk 
of being removed from the market. 
 
DSHEA PROTECTIONS AGAINST 
ADULTERATED “NEW DIETARY 
INGREDIENTS”     
 
The second provision addresses only dietary 
supplements containing new dietary 
ingredients, for which FDA believes there 
may be inadequate information to provide a 
reasonable assurance that the ingredient does 
not present a significant risk of illness or 
injury.  Recognizing that new and untested 
dietary supplement products may pose 
unknown health issues, DSHEA distinguishes 
between products containing dietary 
ingredients that were already on the market 
and products containing new dietary 
ingredients that were not marketed prior to the 
enactment of the law.
17  A “new dietary 
ingredient” is defined as a dietary ingredient 
that was not marketed in the United States 
before October 15, 1994.
18  
 
DSHEA grants FDA greater control over 
supplements containing new dietary 
ingredients.  A new dietary ingredient is 
deemed adulterated and subject to FDA 
enforcement sanctions unless it meets one of 
two exemption criteria: either (1) the 
supplement in question contains “only dietary 
ingredients which have been present in the 
food supply as an article used for food in a 
form in which the food has not been 
chemically altered”; or (2) there is a “history 
of use or other evidence of safety” provided 
by the manufacturer or distributor to FDA at 
least 75 days before introducing the product 
into interstate commerce.
19  The first criterion 
is silent as to how and by whom presence in 
the food supply as food articles without 
chemical alteration is to be established.  The 
second criterion – applicable only to new 
dietary ingredients that have not been present 
in the food supply – requires manufacturers 
and distributors of the product to take certain 
actions.  Those actions include submitting, at 
least 75 days before the product is introduced 
into interstate commerce, information that is 
the basis on which a product containing the 
new dietary ingredient will “reasonably be 
expected to be safe.”
20  That information 
would include: (a) the name of the new 
dietary ingredient and, if it is an herb or 
botanical, the Latin binomial name; (b) a 
description of the dietary supplement that 
contains the new dietary ingredient, including 
the (i) level of the new dietary ingredient in 
the product; (ii) conditions of use of the 
product stated in the labeling or if no 
conditions of use are stated, the ordinary 
conditions of use; and (iii) history of use or 
other evidence of safety establishing that the 
dietary ingredient, when used under the 
conditions recommended or suggested in the 
labeling of the dietary supplement, will be 
reasonably expected to be safe.  
 
There is no guidance as to what evidence is 
required to establish a reasonable expectation 
of safety.
21  In fact, FDA specifically states 
that the person submitting the application is 
responsible for determining what information 
provides the basis for the conclusion that the 
product will be reasonably expected to be 
safe.  By not providing guidance one could 
argue that FDA is giving itself a wide berth to 
arbitrarily decide what ingredients to approve 
or disapprove.  The only hint given is that 
FDA expects the applicant to “consider the 
evidence of safety found in the scientific 
literature, including an examination of 
adverse effects associated with the use of the 
substance.”
22  Thus, it appears that the 
question should be one of safety alone as 
opposed to a safety and efficacy analysis, 
which in turn naturally progresses to a 
risk/benefit analysis.  This is a much different Sports Nutrition Review Journal. 1 (1):52-60, 2004. (www.sportsnutritionsociety.org) 
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and more difficult, if not impossible, standard 
for a NDI to meet. 
 
FDA’S ACTION AGAINST 
ANDROSTENEDIONE 
 
Supplements containing androstenedione 
were introduced in the mid 1990’s and were 
promoted as a natural way to help increase 
strength and muscle mass and to combat the 
effects of the aging process in older men, 
much of which is attributed to declining 
testosterone levels.  Like DHEA, 
androstenedione is a naturally derived 
precursor to testosterone.  Androstenedione 
converts directly to testosterone in the 
metabolic pathway.  The fact that it is 
naturally derived and, as described below 
present in the food supply, is important in 
relation to the action taken by FDA.  
 
In its press release
23 and warning letters
24, 
FDA declared androstenedione to be an 
adulterated new dietary ingredient based on 
its position that no evidence demonstrates 
“that androstenedione was lawfully marketed 
as a dietary ingredient in the United States 
before October 15, 1994.”
25  It would seem to 
be correct that androstenedione was not 
marketed before 1994, given that the first 
commercial marketing of products containing 
androstenedione appears to have been in 
1996.  Further, a review of FDA’s electronic 
database indicates no submission of an 
application for a new dietary ingredient 
involving androstenedione.
26  Interestingly, 
however, FDA goes beyond the words of the 
statute and uses the term “lawfully marketed” 
in their letters instead of simply “marketed.”  
The implication is that to receive 
“grandfathered” status into DSHEA as a pre-
1994 supplement ingredient, the product must 
not only have been marketed but must have 
met the additional requirement of having been 
lawfully marketed.  At least one commentator 
has interpreted this language to impose a 
burden on Industry to prove the product was 
generally regarded as safe pre-1994 – an 
impossible standard for any product that was 
not explicitly affirmed as such by FDA prior 
to the enactment of DSHEA.
27 
 
Assuming that androstenedione is indeed a 
new dietary ingredient, FDA could determine 
that products containing androstenedione are 
adulterated under DSHEA unless they meet 
either of the two exemption criteria stated 
above.   
 
Accordingly, it appears that the question of 
exemption turns on (a) whether or not 
androstenedione is present in the food supply 
as an article used for food without chemical 
alteration, and (b) if not, could the product 
satisfy the requirement of reasonable 
expectation of safety. 
 
With respect to the first exemption, according 
to scientific journals, androstenedione is 
indeed present in the food supply without 
chemical alteration.
28  Had there been open 
communication between FDA and Industry, 
the scientific evidence that androstenedione is 
present in the foods we eat could have been 
presented and discussed with FDA.  
Moreover, until 1998, which is the date for 
the most recent information, there were no 
reports of adverse events reported on FDA’s 
database.
29  Adverse events are one of the few 
specific pieces of information that FDA sets 
forth in their “information” about what safety 
data they require.
30   
 
FDA’s policy creates a nearly impossible 
procedure to demonstrate safety.  FDA’s 
requirements to show safety have never been 
articulated.  On FDA’s web site the following 
statement appears: 
You are not limited in what evidence 
you may rely on in determining 
whether the use of a new dietary 
ingredient will reasonably be 
expected to be safe. (See section 
413(a)(2) of the act (21 U.S.C. 
350b(a)(2)). You must provide a 
history of use or other evidence of 
safety establishing that the dietary 
ingredient, when used under the Sports Nutrition Review Journal. 1 (1):52-60, 2004. (www.sportsnutritionsociety.org) 
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conditions recommended or 
suggested in the labeling of the 
dietary supplement, will reasonably 
be expected to be safe. To date, we 
have not published guidance 
defining the specific information 
that the submission must contain. 
Thus, you are responsible for 
determining what information 
provides the basis for your 
conclusion. Nonetheless, we expect 
that -- in making a determination 
that a new dietary ingredient is 
reasonably expected to be safe, -- 
you will consider the evidence of 
safety found in the scientific 
literature, including an examination 
of adverse effects associated with the 
use of the substance (emphasis 
added).
31 
First, no mention is made of efficacy; the 
necessary component for a risk/benefit 
analysis.  Second, a lack of guidance by FDA 
has created a circular process where at any 
time the agency can declare that the product 
does not satisfy its unspoken standards and 
deem the product adulterated. 
 
Both FDA and Industry must take 
responsibility for this acrimonious and hostile 
environment.  FDA must rid itself of its 
institutionalized bias against supplements and 
have meaningful and cooperative discussions 
with Industry.  Industry must take it upon 
itself to conduct further safety research of its 
products.  If this had been done, the fate of 
androstenedione might have been decidedly 
different.  It is too late to have fruitful 
cooperation between the agency and Industry 
once there are press conferences, press 
releases, warning letters, and products pulled 
from store shelves.  
 
How would FDA have responded if Industry 
had submitted the scientific literature on 
androstenedione to FDA?  What FDA would 
have done is implied in its warning letters.  
After citing androstenedione as an adulterated 
new dietary ingredient, FDA directly 
addresses the safety issue: 
 
Even if the required notification had been 
submitted, based on what we know now, we 
know of no evidence that would establish that 
your product is not adulterated.  In the 
absence of a history of use or other evidence 
of safety establishing that androstenedione, 
when used under the conditions recommended 
or suggested in the labeling of your product, 
will reasonably be expected to be safe, a 
product containing andro is adulterated under 
21 U.S.C. 342(f)(1)(B) and 350b(a) as a 
dietary supplement that contains a new 
dietary ingredient for which there is 
inadequate information to provide reasonable 
assurance that such ingredient does not 
present a significant or unreasonable risk of 
illness or injury.
32 
 
Thus, FDA suggests that even if industry had 
provided proper notification pursuant to 
statute, its position is that there exists 
inadequate information from which to 
conclude that androstenedione could be 
reasonably expected to be safe as a dietary 
ingredient.  In fact, FDA believes to the 
contrary according to its androstenedione 
“Questions and Answers” web page: 
 
Based on a limited number of studies 
of andro’s actions in humans and 
existing knowledge about steroid 
hormone metabolism and action in 
the body, FDA believes that the use 
of dietary supplements containing 
andro may increase the risk of 
serious health problems because of 
their conversion in the body to active 
hormones with androgenic and 
estrogenic properties.
33  
 
A review of the “limited number” of andro 
studies and a scientific analysis of their 
meaning is beyond the scope of this article.
34  
However, if Industry desires to continue to 
develop and market innovative new dietary 
products it is going to have to adopt a more 
aggressive role in conducting research and Sports Nutrition Review Journal. 1 (1):52-60, 2004. (www.sportsnutritionsociety.org) 
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publishing studies.  It is going to have to 
forge stronger and more extensive 
relationships with the scientific community to 
analyze its products and their effects.  It is 
then going to have to ensure that those studies 
are brought to the attention of the FDA and 
others. 
 
RAMIFICATIONS FOR THE DIETARY 
SUPPLEMENT INDUSTRY  
 
The next question that must be asked is what 
does this mean for other dietary supplements?  
The loss of ephedra and androstenedione are 
strong signals of FDA’s intent to reach as far 
as possible in their attempt to regulate 
supplements.  Anyone attuned to what is 
transpiring in this Industry is aware that there 
is a movement to undo most of the framework 
of DSHEA.  The fallout may have 
ramifications far beyond the fitness nutrition 
community, impacting the mainstream 
vitamin industry and traditional herbalists. 
 
Senator Richard Durbin of Illinois, a long-
time critic and opponent of the dietary 
supplement industry, recently addressed 
Congress in promoting a bill he is 
sponsoring that would put safety burdens on 
Industry and criminalize certain 
supplements: 
  
People unsuspectingly go into these 
health food stores, vitamin stores, and 
see the dietary supplements with all 
sorts of claims on them; they buy them, 
they use them, and the consumers of 
America become the guinea pigs. 
… 
[I]f they are dangerous, if they hurt 
someone, clearly then the Government 
will take them off the shelf, right? No, I 
am sorry, that is not right because 
understand that the law we passed at 
the request of the industry does not 
require dietary supplement 
manufacturers to report to the 
Government when people are literally 
dying from the products they sell. 
… 
I am happy to see the Institute of 
Medicine creating momentum for 
Congress to finally make a decision.  I 
am happy to see the administration, 
after more than a year of urging, 
finally banning ephedra, but more has 
to be done. Today as we speak, 
innocent children and consumers 
across America are buying products 
which they presume to be safe and they 
are not.
35 
 
The Senator’s statement about the Institute 
of Medicine of the National Academies 
refers to a recent publication suggesting a 
new framework for evaluating the safety 
of dietary supplement ingredients,
36 using 
a “spectrum of concern” model more 
appropriate to the review of prescription 
drugs.  While the effort is a noble one, 
Industry should be careful that such an 
approach is not the first step backwards 
towards a pre-DSHEA environment and a 
movement to define many dietary 
supplement ingredients as drugs. 
 
No one can or should object that 
manufacturers and distributors of products 
should be able to substantiate the claims 
they make about their products.  No one 
can argue that safety research on products 
should be conducted.  Any company that 
manufactures or distributes dietary 
supplements should have a comprehensive 
policy for handling reports of serious 
adverse health events.  Finally, any 
manufacturer or distributor should have 
proper labels on their products with 
appropriate cautions and warnings. 
 
There also needs to be more rational 
reporting within the media.  An extreme 
example of the media bias against sports 
supplements involved the reported story of 
a 22-year-old “would-be bodybuilder” 
who claimed that his use of creatine 
monohydrate at recommended doses for 
three and a half months caused liver and 
kidney failure and the loss of the full use 
of his legs.
37  The story begins by Sports Nutrition Review Journal. 1 (1):52-60, 2004. (www.sportsnutritionsociety.org) 
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describing the “deep blue and red scar 
[that] carves the skin on the outside of 
both of [his] legs, from his hips to his 
ankles.  Orthopedic surgeons' scalpels 
have sliced them open again and again 
over the past five months to save his life 
and legs.”  It continues with: “‘After the 
fourth day they wanted to amputate both 
legs at the hip,’ he said.  ‘They were afraid 
the decay would spread to my lower 
intestines.’”  Finally, the story proceeds to: 
“What caused all the problems? ‘The 
doctors … told me it was the creatine,’ he 
said.  ‘My body wouldn’t process it.’  It 
ended up poisoning him.”  The story was 
tossed to the public without any comments 
from nutrition experts or even the doctors 
who supposedly attributed the horrific 
symptoms to creatine.  This disconnect 
between the fitness community’s 
experience with these products and the 
questionable scare stories reported by the 
media does nothing but perpetuate an 
atmosphere of confusion and mistrust. 
 
More importantly, FDA must also assume 
some responsibility for this state of affairs.  
If Industry is going to be compelled to 
institute policies and procedures then there 
must also be changes within FDA.  This 
means a change in attitude towards 
supplements, hiring people within the 
FDA Center for Food Safety and Applied 
Nutrition (CFSAN) responsible for 
supplements who understand and support 
the use of supplements and the 
appointment of an ombudsman within 
CFSAN as there are in other centers within 
FDA. 
 
This lack of guidance and communication 
with FDA makes it very difficult for anyone 
to know whether or not they could even 
comply with FDA’s requirements.  As was 
evidenced by the process in Ephedra, FDA 
did not, in any meaningful way, communicate 
with Industry to learn about Industry’s 
experiences.  Even after Industry compiled a 
marketing study
38, FDA did not communicate 
with Industry about the findings.
39  The lack 
of communication between FDA and Industry 
fosters an atmosphere of frustration and 
suspicion that benefits neither FDA nor 
Industry, and most importantly is a detriment 
to the American public.  Until there is better 
cooperation and communication between 
FDA and Industry and until there are people 
within FDA who support the use of dietary 
supplements this will continue to be a 
problem.  
 
It is hoped that before FDA takes any other 
actions or makes any other pronouncements 
about dietary supplement ingredients, a 
mutually cooperative dialogue can take place.  
Even if that were to occur, however, there is 
another issue to consider.  While FDA 
enforcement against other dietary supplement 
ingredients is possible, future action may be 
legislative rather than regulatory.  Several 
federal bills are pending which would relegate 
prohormone products to controlled substance 
status, making their distribution a federal 
felony and their mere possession by health-
conscious, adult consumers a federal crime.
40  
This illogical step has no basis in fact given 
that there is no scientific evidence that 
prohormone products meet the test of a 
controlled substance.  Controlled substances 
are drugs – such as cocaine, heroin and LSD – 
or other substances with addictive qualities 
that may lead to physical or psychological 
dependence.
41  There is not a scintilla of 
evidence that these products have been 
exerting addictive effects or leading to 
dependency issues.  The momentum behind 
legislative action is due more to the current 
media frenzy over the use of steroidal 
“doping” in sports.  Regulating these products 
is taking the more political route of legislation 
than regulation by FDA after notice and 
comment.  There is the very real possibility 
that all prohormone products will be 
legislatively removed from the marketplace 
without scientific or factual support.   
 
CONCLUSION 
 
FDA’s action on androstenedione suggests a 
heightened enforcement policy against what Sports Nutrition Review Journal. 1 (1):52-60, 2004. (www.sportsnutritionsociety.org) 
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the agency deems to be adulterated new 
dietary ingredients.  Bringing products to 
market that do not meet either of the two 
exemption criteria of 21 U.S.C. 350(b) may 
not be overlooked in the future.  If a new 
dietary ingredient is exempted from 
adulterated status because it is present in the 
food supply as an article used for food in a 
form in which the food has not been 
chemically altered, it is prudent to document 
that information prior to marketing the 
product or even to communicate that 
information to FDA.  If a new dietary 
ingredient is not exempted from adulterated 
status based upon the food supply exemption, 
then pre-market notification of history of use 
or other evidence of safety establishing that 
the dietary ingredient, when used under the 
conditions recommended or suggested in the 
labeling of the dietary supplement, will be 
reasonably expected to be safe must be 
provided to FDA at least 75 days before the 
product is introduced into interstate 
commerce.  
The dietary supplement industry as regulated 
by DSHEA is still a relatively new industry.  
Like any new industry it is going through 
growing pains.  However, for the industry to 
survive it must begin to attempt to establish 
communication with legislative 
representatives and administrative agencies, 
like FDA.  It must begin an era of cooperation 
among its members, no matter how 
competitive they may be in business, to 
establish procedures and to develop science.  
Failure to do so will result in constantly being 
buffeted by the winds of public opinion and 
sensationalistic journalism.  At the same time, 
our representatives and government officials 
must take a close look at the inherent and 
institutionalized bias that exists against 
dietary supplements within government and 
begin to find ways to undo that bias so that 
productive and meaningful dialogue can take 
place.  Until that happens, the American 
public will be disadvantaged. 
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